BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220209
DTEND;VALUE=DATE:20220211
DTSTAMP:20260515T235347
CREATED:20211013T105724Z
LAST-MODIFIED:20220114T094327Z
UID:31828-1644364800-1644537599@www.pharmajournalist.com
SUMMARY:SMi’s 13th Annual RNA Therapeutics Conference
DESCRIPTION:SMi Group’s 13th Annual Conference: \nRNA Therapeutics 2022\n9th – 10th February 2022\nVirtual Conference: Online Access Only\nwww.therapeutics-rna.com \nSponsored by: BIA Separations | eTheRNA Immunotherapies | Thermo Fisher Scientific \nBolstering the latest advances and opportunities in RNA-based medicine \nThe RNA therapeutics industry has grown at an exponential rate in recent years\, with an increased spotlight following the industry’s leading role in developing vaccines against COVID-19 in response to the global pandemic. This year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development. \nThe 2022 agenda will explore innovations in novel and targeted delivery\, RNAi innovations and antisense oligonucleotide therapeutics. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of RNA with case studies on the treatment of cardiovascular disease\, neurological diseases\, and oncology.
URL:https://www.pharmajournalist.com/event/smis-13th-annual-rna-therapeutics-conference/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="SMi Group Ltd":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220209
DTEND;VALUE=DATE:20220211
DTSTAMP:20260515T235347
CREATED:20211210T000811Z
LAST-MODIFIED:20220117T123916Z
UID:32418-1644364800-1644537599@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual 3D Cell Culture Conference
DESCRIPTION:SMi’s 5th Annual 3D Cell Culture Conference \nVirtual Conference: Online Access Only \n9-10 February 2022 \nhttp://www.3d-cellculture.com/ \nSponsored by: CELLINK\, CelVivo\, Promega and Newcells BiotechDeveloping Complex\, Translatable and Physiologically-Relevant Cellular Models in vitro \nConference Co-Chairs: Stefan Przyborski\, Professor of Cell Technology\, Durham University and Philip Hewitt\, Global Head of Early Investigative Toxicology\, Merck \n3D Cell Culture is gaining momentum in the pharmaceutical industry on account of the advantages such models pose for in drug discovery\, from improved clinical translation and predictivity\, to patient safety and sustainability. \nSMi’s 3D Cell Culture Conference will explore advances in the application of 3D cell models\, from their employment in drug screening to reduce candidate attrition\, to the latest insights into microphysiological systems\, the regulatory landscape\, and the clinical applications of 3D bioprinting. \nEvent Hashtag: #SMi3DCellCulture \nKey Benefits of Attending: \n\nDiscuss the uses of advanced cell technologies to construct in vitro models of human tissues\nExplore the regulatory sciences surrounding Microphysiological systems\, and their development and adoption for drug safety assessment\nUncover the major benefits of 3D modelling in enhancing clinical translation and predictability\nUtilise 3D cell culture for High Throughput drug discovery and Content screening over traditional 2D methods\n\n\n• Delve into advanced case studies looking into organ models: from organotypic lungs to liver spheroids\n\n WHO SHOULD ATTEND? \nBiotech / Pharma Companies – Team Leader\, Junior Principle investigator\, Cell and Molecular Scientist\, Chief Scientific Officer\, Deputy Director\, Manager\, Founder\, CEO\, Head\, Director\, Programme Manager\, Lab Head\, Toxicologist \nAcademia Professor – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering \nSolution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer
URL:https://www.pharmajournalist.com/event/smis-5th-annual-3d-cell-culture-conference-2022/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220214
DTEND;VALUE=DATE:20220217
DTSTAMP:20260515T235347
CREATED:20211029T081249Z
LAST-MODIFIED:20211029T081249Z
UID:31932-1644796800-1645055999@www.pharmajournalist.com
SUMMARY:4th Bacteriophage Therapy Summit
DESCRIPTION:From Translation to Market-Entry: Advance Formulation\, Clinical Development\, & Commercialization of Phage-Based Therapies at the 4th Bacteriophage Therapy Summit 2022. \nReturning for its 4th year\, the Bacteriophage Therapy Summit remains the only industry-focused forum dedicated to facilitating the discovery\, translation & acceleration of bacteriophage research into targeted therapeutics with clinically significant results. View the full event guide here: https://ter.li/ehl7e1 \n2022 Agenda Overview: \n\nNavigate clinical trial rationale\, distribution effects of formulation on reaching infection sites\, lessons learned from compassionate use trials\, and the regulatory pathway for commercial development with the hottest insights from our 35+ expert speaker faculty\nHear from international organizations including the FDA\, BiomX\, Locus Bioscience\, Felix Bioscience\, Phagomed\, PhagePro\, Cytophage\, Sciphage and unite with the phage community prioritizing human health and diseas\nDiscuss strategies to weaponize phage therapies including lysins\, genetic engineered and combination approaches to create new pathways for the treatment of infectious diseases\, across 3 days of unparalleled\, industry-centered content\nKeep your company’s interest in bacteriophage therapies up-to-date and aligned with the new breakthroughs beyond basic science and establish your pathway to commercialization in 2022 and beyond\n\nSee our full speaker faculty\, all agenda topics\, and our attending audience in our event brochure: https://ter.li/ehl7e1 \nJoin us to develop the next generation of phage therapy products disrupting the medical and healthcare industries for a better tomorrow. Early booking and group discounts are available upon request. Please visit the website for more information on registration fees and discounts. https://ter.li/1szl1y
URL:https://www.pharmajournalist.com/event/4th-bacteriophage-therapy-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220215
DTEND;VALUE=DATE:20220218
DTSTAMP:20260515T235347
CREATED:20211105T123049Z
LAST-MODIFIED:20211105T123049Z
UID:31997-1644883200-1645142399@www.pharmajournalist.com
SUMMARY:2nd Operationalize: Expanded Access Programs Summit
DESCRIPTION:This 2nd Operationalize: Expanded Access Programs summit is here to bring you solutions. \nBy bringing together the world’s leading Expanded Access Programs thinkers\, this exclusive platform will clarify the complex issues through end-to-end Managed Access/Compassionate Use program operationalization. Through open discussion\, sharing best-practice case studies\, and removing hypotheticals: this event provides an unrivaled opportunity to solve your challenges across the entire timeline. \nWhether it’s program set-up\, US and EU regulatory pathways\, product supply\, data collection\, logistics\, ethical considerations\, or internal collaborating – ensure you aren’t repeating past mistakes by hearing global leaders recall their experiences with a shared goal of providing you with pragmatic solutions to solve these complex hurdles. \nFor more information visit: https://ter.li/f41rv0
URL:https://www.pharmajournalist.com/event/2nd-operationalize-expanded-access-programs-summit/
LOCATION:Aloft Boston Seaport District\, 401-403 D St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220221
DTEND;VALUE=DATE:20220224
DTSTAMP:20260515T235347
CREATED:20211202T111335Z
LAST-MODIFIED:20211202T111335Z
UID:32303-1645401600-1645660799@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences Europe
DESCRIPTION:LEAP HR: Life Sciences Europe is your best opportunity to uncover the brand-new HR thinking that will enable you to tackle an ongoing talent shortage\, and create the differentiated people strategies and organisational agendas you need to thrive in a hybrid life sciences operating environment. \n \nStep inside 20+ case studies of how biopharma organisations of all sizes are thriving in new-hybrid working models – and leave with the inspiration you need to transform HR impact in your own organisation.  Look beyond what’s previously not been possible and focus on how HR can transform its strategic impact in this fundamentally new working world that will enable your own organisation to compete more effectively for top life sciences talent. \nFind out more > https://ter.li/tw2ss2
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-europe/
LOCATION:The Pestana Amsterdam Riverside\, Amsteldijk 67\, Amsterdam\, 1074 HZ\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260515T235347
CREATED:20211101T103734Z
LAST-MODIFIED:20211101T103819Z
UID:31980-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:3rd RAS/MAPK Pathway Targeted Drug Discovery Summit
DESCRIPTION:The Only Global RAS Dedicated Conference is Returning in 2022 with the 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit!\nYear on year\, we are proud to unite the leading frontiers of the RAS industry to showcase expertise\, technical data and pipeline updates\, all geared toward accelerating the discovery and development of anti-RAS therapies. \nThis February 2022\, the summit returns to shine a spotlight onto pioneering discoveries and innovative strategies to target RAS\, including a focus on success in targeting mutations beyond G12C and efforts to shut down the RAS/MAPK pathway at every turn. \nAs the industry springboards off the significant success of G12C covalent inhibitors against KRAS mutant cancers\, leading experts are now shifting focus toward next-generation anti-RAS drugs\, considering how we can leverage the RAS signaling pathway to treat all RAS mutant cancers\, and overcome the critical escape mechanisms leading to treatment resistance. \nTo know more visit: https://ter.li/8ljo2k
URL:https://www.pharmajournalist.com/event/3rd-ras-mapk-pathway-targeted-drug-discovery-summit/
LOCATION:8:30am – 5pm | Boston\, MA In-Person and Digital Options Available
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260515T235347
CREATED:20211109T113013Z
LAST-MODIFIED:20211109T113013Z
UID:32042-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:Next Generation CAR-TCR Summit
DESCRIPTION:As the CAR-T field continues to explode with new companies\, investment\, and clinical collaborations\, it’s more important than ever to stay ahead of the curve. Stakeholders across oncology are now turning to next generation developments and innovations to create the therapies of tomorrow. \nThat’s why CAR-TCR Europe has evolved into the Next Generation CAR-TCR Summit: your definitive platform focused on the 2.0\, next generation innovations in cell therapies. \nJoin you CAR-TCR community and network with 300+ innovators from large pharma\, biotech\, academia and regulatory boards at the only meeting dedicated to accelerating novel\, new generation cell therapies that are safer\, more effective and have meaningful impact in diseases beyond oncology. \nYou’ll hear insights into novel in-vivo delivery\, innovations in gene\, base & prime editing\, novel discovery platforms\, overcoming the hostile tumour microenvironment\, improving persistence & durability for greater clinical outcomes\, and more! \nKey insights will be shared from Matterhorn Biosciences\, Affini-T Therapeutics\, Kiromic BioPharma\, Antion Biosciences\, Zelluna Immunotherapy\, T-Kinfe Therapeutics\, AffyImmune and many more. Leverage their knowledge to deliver value to your entire cell therapy team. \nWith 3 in-depth streams exploring the hottest Novel Platforms\, Advanced Clinical Development of 3rd\, 4th and 5th generation cell therapies\, and the latest Manufacturing Innovations to revolutionise the production of large-scale cell therapy\, this is the ONLY meeting bringing you the next generation developments and innovations needed to create the therapies of tomorrow. \nWhether you are developing novel constructs\, new clinical trial strategies or innovative manufacturing approaches for large scale production\, this multi-tracked meeting can support your whole team and provide the tools needed to advance your own pipeline towards clinical and commercial success. \nView official event guide now for the full meeting details!
URL:https://www.pharmajournalist.com/event/next-generation-car-tcr-summit/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260515T235347
CREATED:20211129T180236Z
LAST-MODIFIED:20211129T180236Z
UID:32287-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:2nd Mitochondria-Targeted Drug Development Summit
DESCRIPTION:We are happy to announce that the Mitochondria-Targeted Drug Development Summit\, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction\, will be delivered in-person\, for its 2nd edition.\nMitobridge/Astellas\, Minovia Therapeutics\, Abliva\, GenSight Biologics\, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies. \nTo know more visit: https://mitochondria-targets.com/
URL:https://www.pharmajournalist.com/event/2nd-mitochondria-targeted-drug-development-summit/
LOCATION:Hyatt Regency Boston / Cambridge\, 575 Memorial Dr\, Cambridge\, MA\, 02139\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR